Vicinitas Therapeutics
Vicinitas Therapeutics develops targeted protein degradation therapies using its Deubiquitinase Targeting Chimera (DUBTAC) platform to treat diseases caused by aberrant protein stability.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
About
Vicinitas Therapeutics develops targeted protein degradation therapies using its Deubiquitinase Targeting Chimera (DUBTAC) platform to treat diseases caused by aberrant protein stability.
OncologyRare DiseaseProteomics
Funding History
1Total raised:$65M
Venture$65M